Results 61 to 70 of about 38,200 (304)

SOX5 Orchestrates Malignant Evolution via Promoter‐Centric Chromatin Remodeling in MYC‐Driven B‐Cell Lymphoma

open access: yesAdvanced Science, EarlyView.
In MYC‐enforced B‐cell lymphoma, SOX5 occupies promoter‐proximal regulatory regions and is associated with reduced chromatin accessibility at the PCNP locus. PCNP repression promotes proliferative remodeling by limiting apoptosis and cell‐cycle restraint.
Yiyou Mao   +6 more
wiley   +1 more source

Pharmacogenomics perspective for forensic toxicology: A mini review

open access: yesMedicine Science, 2022
Pharmacogenetic and Pharmacogenomics are the study of the association between an individual's genotype and their response to xenobiotics Pharmacokinetic and pharmacodynamics variations can appear at the level of drug-metabolizing enzymes, drug ...
Dilek Battal   +3 more
doaj   +1 more source

Targeting the PHB2–ACSL3 Lipid‐Remodeling Axis Overcomes Cisplatin Resistance by Restoring Ferroptosis in Gastric Cancer

open access: yesAdvanced Science, EarlyView.
ABSTRACT Platinum‐based chemotherapy resistance remains a major obstacle in gastric cancer (GC) treatment. Through integrated transcriptomic profiling of cisplatin‐resistant xenografts and pharmacogenomic interrogation of the NCI‐60 dataset, we identified Prohibitin‐2 (PHB2) as a previously unrecognized determinant of chemoresistance.
Liang Xu   +10 more
wiley   +1 more source

The needs and gaps in pharmacogenomics knowledge and education among healthcare professionals in Malaysia: A multisite Delphi study

open access: yesClinical and Translational Science
Lack of pharmacogenomics knowledge among healthcare professionals is the most significant cited barrier to implementing pharmacogenomics in clinical settings.
Safa Omran   +5 more
doaj   +1 more source

Clinical practice guidelines for translating pharmacogenomic knowledge to bedside. Focus on anticancer drugs.

open access: yesFrontiers in Pharmacology, 2014
The development of clinical practice recommendations or guidelines for the clinical use of pharmacogenomics data is an essential issue for improving drug therapy, particularly for drugs with high toxicity and/or narrow therapeutic index such as ...
José A G Agúndez   +7 more
doaj   +1 more source

Cardiovascular Pharmacogenomics

open access: yes, 2017
Background: Variability in response to pharmacological treatment is one of the most important issues in the clinical practice at first exclusively attributed to clinical and demographic factors such as age, sex, nutritional status, alcohol abuse, smoking,
FILIPPELLI, Amelia   +11 more
core   +1 more source

AI‐Driven Cancer Multi‐Omics: A Review From the Data Pipeline Perspective

open access: yesAdvanced Intelligent Discovery, EarlyView.
The exponential growth of cancer multi‐omics data brings opportunities and challenges for precision oncology. This review systematically examines AI's role in addressing these challenges, covering generative models, integration architectures, Explainable AI for clinical trust, clinical applications, and key directions for clinical translation.
Shilong Liu, Shunxiang Li, Kun Qian
wiley   +1 more source

Implementing health economics for pharmacogenomics research translation in Africa

open access: yesCommunications Medicine
Pharmacogenomics studies how a person’s inherited genes influence response to therapeutic drugs. Many drugs do not work in all patients and pharmacogenomics can assist in the identification of patients who are better suited to particular drugs or ...
Mohamed Zahir Alimohamed   +4 more
doaj   +1 more source

Knowledge, Perception, and Application of Pharmacogenomics Among Hospital Pharmacists in Saudi Arabia

open access: yesRisk Management and Healthcare Policy, 2020
Mohammed Algahtani Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, Kingdom of Saudi ArabiaCorrespondence: Mohammed Algahtani Email msalqahtane@nu.edu.saIntroduction: The accelerated transformation in the healthcare system ...
Algahtani M
doaj  

Integrating Genetic Modifier Genotype With Serum Proteomics in Duchenne Muscular Dystrophy Clinical Trials Links LTBP4 Genetic Modifier to IL‐23/CD93 Pathways in Muscle

open access: yesAmerican Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Genetic modifiers of Duchenne muscular dystrophy (DMD) that alter disease severity or response to therapy have been reported using natural history or registry data sets of older corticosteroid‐treated patients. We tested associations of genetic modifiers on motor function outcomes in young (4 to < 7 years) steroid naïve clinical trial ...
Utkarsh J. Dang   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy